Incyte to Present Long-Term Povorcitinib Data for Hidradenitis Suppurativa at AAD 2026
Key Insights
Incyte will present late-breaking 54-week efficacy and safety data from the Phase 3 STOP-HS1 and STOP-HS2 studies evaluating povorcitinib in moderate to severe hidradenitis suppurativa (search) patients.
The company will showcase multiple presentations on its inflammation and autoimmunity franchise, including data on ruxolitinib cream (Opzelura) for atopic dermatitis (search) and vitiligo (search).
Povorcitinib is an oral JAK1 (search) selective inhibitor currently in Phase 3 trials for hidradenitis suppurativa (search), vitiligo (search), and prurigo nodularis (search), with additional Phase 2 development in asthma (search).
Incyte Corporation announced it will present extended clinical data from its inflammation and autoimmunity pipeline at the 2026 American Academy of Dermatology (AAD) Annual Meeting, scheduled for March 27-31, 2026, in Denver. The company will highlight 54-week results from its Phase 3 STOP-HS program evaluating povorcitinib in patients with moderate to severe hidradenitis suppurativa (search).
Extended Efficacy Data for Hidradenitis Suppurativa
The centerpiece presentation will feature late-breaking oral data from the STOP-HS1 and STOP-HS2 Phase 3 studies, providing longer-term evidence of povorcitinib's safety and efficacy profile in hidradenitis suppurativa (search) patients. According to Jim Lee, M.D., Ph.D., Group Vice President of Inflammation and Autoimmunity at Incyte, "These data provide longer term evidence of the safety and efficacy of povorcitinib in HS patients and further strengthen the significant growth potential of our Inflammation and Autoimmunity franchise."
The late-breaking oral presentation, titled "Povorcitinib in Patients With Moderate to Severe Hidradenitis Suppurativa (search): 54-Week Efficacy and Safety Results From the STOP-HS1 & STOP-HS2 Phase 3 Studies," is scheduled for Saturday, March 28, 2026, at 1:00 p.m. MT during Session S034.
Comprehensive Dermatology Portfolio Showcase
Beyond the hidradenitis suppurativa (search) data, Incyte will present multiple ePoster exhibits covering its broader dermatology portfolio. The presentations include data on ruxolitinib cream (Opzelura) in atopic dermatitis (search), demonstrating improved patient-reported outcomes in adults with moderate disease and efficacy regardless of baseline disease severity and previous medication history.
Additional hidradenitis suppurativa (search) presentations will include week 24 interim Phase 3 results for povorcitinib in anti-TNF-experienced patients, along with physician and patient perspectives from the global HERALD survey examining real-world experiences with the condition.
The vitiligo (search) program will be represented through presentations examining the association between repigmentation and quality of life in patients treated with ruxolitinib cream in the TRuE-V studies, as well as real-world factors influencing vitiligo care.
JAK Inhibitor Development Programs
Povorcitinib (INCB54707) represents Incyte's oral small-molecule JAK1 (search) selective inhibitor currently advancing through Phase 3 clinical trials for hidradenitis suppurativa (search), vitiligo (search), and prurigo nodularis (search), with additional Phase 2 development in asthma (search). This selective approach targets the JAK1 pathway while potentially minimizing broader immunosuppressive effects associated with less selective JAK inhibition.
Opzelura (ruxolitinib) cream, Incyte's topical JAK1 (search)/JAK2 (search) inhibitor, has established regulatory approval in the United States as the first and only treatment for repigmentation in nonsegmental vitiligo (search) patients 12 years of age and older. The cream is also approved for topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (search) in non-immunocompromised patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies.
In Europe, Opzelura cream 15mg/g is approved for treating non-segmental vitiligo (search) with facial involvement in adults and adolescents from 12 years of age. The product carries recommendations against use in combination with therapeutic biologics, other JAK inhibitors, or potent immunosuppressants such as azathioprine or cyclosporine.
Strategic Franchise Development
The AAD presentations underscore Incyte's strategic focus on expanding its inflammation and autoimmunity franchise beyond its established hematology and oncology portfolios. The company has built what it describes as "an established portfolio of first-in-class medicines and an extensive portfolio of next-generation medicines" across its key therapeutic areas.
The 54-week data from the STOP-HS program represents a significant milestone in demonstrating the durability of povorcitinib's therapeutic effects in hidradenitis suppurativa (search), a chronic inflammatory skin condition that significantly impacts patient quality of life. The extended follow-up period provides crucial insights into the long-term safety and efficacy profile necessary for regulatory submissions and clinical adoption.